ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA
- Mocertatug rezetecan (HS-20089, a B7-H4-Targeted ADC), as monotherapy and in combination with bevacizumab, showed anti-tumor activity with a managea...
2026.02.28